周二，美国银行证券 (BofA Securities)调整了Denali Therapeutics Inc. (NASDAQ:DNLI)的股票目标价，将其从之前的34美元下调至30美元，同时维持对该股的买入评级。根据 InvestingPro ...

分析师评论了Denali最近的股价下跌，将其归因于更广泛的市场趋势，而非公司特定消息。Denali的股价回调反映了XBI生物技术指数的走势，被认为是整体投资组合定位转变的一部分，在高利率环境下，较大的基金可能减少了生物技术领域的敞口。

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

While GMC eventually went with the Denali name, this was right around the same time Toyota was working on the ...